Shattuck Labs (NASDAQ:STTK) Stock Rating Reaffirmed by HC Wainwright

Shattuck Labs (NASDAQ:STTK)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They presently have a $16.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 324.40% from the company’s previous close.

STTK has been the topic of several other research reports. BTIG Research lowered Shattuck Labs from a “buy” rating to a “neutral” rating in a report on Monday, June 17th. Needham & Company LLC cut their price target on Shattuck Labs from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, June 14th. Finally, Citigroup cut their price target on Shattuck Labs from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, June 17th.

Shattuck Labs Price Performance

Shares of Shattuck Labs stock opened at $3.77 on Friday. Shattuck Labs has a one year low of $1.33 and a one year high of $11.76. The stock’s 50-day moving average is $5.09 and its 200 day moving average is $7.85. The firm has a market cap of $179.26 million, a price-to-earnings ratio of -1.95 and a beta of 1.73.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Thursday, May 2nd. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.08. Shattuck Labs had a negative return on equity of 64.85% and a negative net margin of 3,133.63%. The company had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.30 million. The business’s revenue was up 2200.0% on a year-over-year basis. On average, sell-side analysts expect that Shattuck Labs will post -1.56 EPS for the current fiscal year.

Insider Activity

In related news, CEO Taylor Schreiber bought 14,400 shares of the company’s stock in a transaction dated Wednesday, June 26th. The shares were bought at an average price of $3.47 per share, for a total transaction of $49,968.00. Following the completion of the acquisition, the chief executive officer now directly owns 34,502 shares of the company’s stock, valued at $119,721.94. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of STTK. SG Americas Securities LLC purchased a new position in Shattuck Labs in the fourth quarter worth $268,000. Reliant Investment Management LLC bought a new stake in shares of Shattuck Labs in the fourth quarter valued at $143,000. Franklin Resources Inc. bought a new stake in shares of Shattuck Labs in the fourth quarter valued at $11,663,000. Monashee Investment Management LLC bought a new stake in shares of Shattuck Labs in the fourth quarter valued at $713,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Shattuck Labs by 79.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company’s stock valued at $97,000 after buying an additional 5,989 shares during the period. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.